SCHEMBL6355306

SCHEMBL6355306

O=C(NCc1ccccc1CCc1ccccc1)c1cccc(Cl)c1Cl

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.74
ALDH1A1 P00352 5/20 0.61
LMNA P02545 3/20 0.61
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
TMEM97 Q5BJF2 2/20 0.53
SIGMAR1 Q99720 2/20 0.53
POLB P06746 1/20 0.51
HPGD P15428 2/20 0.50
MAPK8 P45983 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
SCN5A Q14524 1/20 0.50
SCN2A Q99250 1/20 0.50
P2RX7 Q99572 1/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
ADRB2 P07550 1/20 0.48
GPR139 Q6DWJ6 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6355282 0.88 L3MBTL1 (0.60) L3MBTL1ALDH1A1LMNANPC1RAB9A
SCHEMBL6361006 0.83 L3MBTL1 (0.58) L3MBTL1ALDH1A1LMNANPC1RAB9A
SCHEMBL6357294 0.83 L3MBTL1 (0.55) L3MBTL1ALDH1A1LMNANPC1RAB9A
SCHEMBL6355484 0.82 L3MBTL1 (0.56) L3MBTL1ALDH1A1LMNANPC1RAB9A
SCHEMBL6358813 0.81 MT-CO2 (0.65) L3MBTL1ALDH1A1LMNANPC1RAB9A
SCHEMBL6357846 0.80 SGMS2 (0.61) L3MBTL1ALDH1A1LMNANPC1RAB9A
SCHEMBL6356912 0.80 CHRNB2 (0.59) L3MBTL1ALDH1A1LMNATMEM97SIGMAR1
SCHEMBL6356702 0.80 MAPK8 (0.57) L3MBTL1ALDH1A1LMNANPC1RAB9A
SCHEMBL6355939 0.78 MT-CO2 (0.53) L3MBTL1ALDH1A1LMNATMEM97SIGMAR1
SCHEMBL6356156 0.77 ALDH1A1 (0.75) L3MBTL1ALDH1A1LMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 L3MBTL1 2120/4885ALDH1A1 1194/4885LMNA 1197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.